Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Private biotech Tenpoint emerged in 2023 with $70 million and a regenerative medicine platform. The company was previously ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...